Melphalan Causes Second Cancer in Multiple Myeloma, not Revlimid

Second cancers, often the result of treatments received, are an especially big concern in the treatment of multiple myeloma.

Previous studies have linked various sources to an increased risk of second cancers in these patients, but a new study may give doctors and patients some ease when using one of the more novel agents to fight this disease.

Findings from this retrospective study may help ease concerns among multiple myeloma patients and their doctors about using Revlimid (lenalidomide) to treat their disease.

Researchers determined that patients given Revlimid in combination with low-dose oral melphalan (as opposed to high-dose melphalan, common in stem cell transplants) are five times as likely to develop a second blood cancer compared with those patients who receive melphalan alone.

Research team recommends certain course of drugs

This is in line with prior research done in the field that has shown an increased risk of second cancers with long-term melphalan exposure, as well as an increased risk of second cancers in newly diagnosed patients given Revlimid plus Melphalan, but not in those given Revlimid plus dexamethasone.

In order to avoid putting patients newly diagnosed with multiple myeloma at greater risk of developing second cancers, the research team, led by Antonio Palumbo, M.D., recommends using cyclophosphamide instead of melphalan or a drug similar to cyclophosphamide but not a drug that works in the manner that melphalan does in order to reduce the risk of second cancers in these patients.

Source: Lancet Oncology

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap